Forte Biosciences, Inc.
fortebiorx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2026 10-Q, filed Aug 12, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Sep 8, 2026.
10-Q for Q2 FY2026, filed Aug 12, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops an antibody drug candidate for autoimmune and autoimmune-related diseases, including celiac disease, vitiligo and alopecia areata.
10-K for FY2025, filed Mar 31, 2026Forte Biosciences, Inc. and its subsidiaries (www.fortebiorx.com) (“Forte”, “we”, “our”) is a clinical-stage biopharmaceutical company…View ↗
Three cohorts of single and two cohorts of multiple ascending doses in a Phase 1 trial of healthy volunteers were completed in which FB102…View ↗
Based on the successful completion of our patient-based Phase 1b celiac disease study, we initiated a Phase 2 celiac study in July 2025…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$23.3MView ↗
- ▲ +107% (Loss)
- vs −$11.2M in Q2 FY2025
-
Aug 27, 2026
argenx completed its acquisition of Forte
Forte became a wholly owned subsidiary, and shareholders received cash for their shares.
Sources
8-K, filed Aug 27, 2026
Following the consummation of the Offer, the remaining conditions to the Merger (as defined below) set forth in the Merger Agreement were…View ↗
-
Jul 27, 2026
argenx agreed to acquire Forte for cash
The proposed acquisition was structured as a tender offer followed by a merger.
Sources
8-K, filed Jul 27, 2026
On July 26, 2026, Forte Biosciences, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the…View ↗
Clinical development
The earlier report described the candidate in preclinical development; the latest describes completed healthy-volunteer testing and patient trials in celiac disease, vitiligo and alopecia areata.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026Forte Biosciences, Inc. and its subsidiaries (www.fortebiorx.com) (“Forte”, “we”, “our”) is a biopharmaceutical company that is advancing…View ↗
Indications under study
The earlier report highlighted graft-versus-host disease, vitiligo and alopecia areata, while the latest describes patient trials in celiac disease, vitiligo and alopecia areata.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026Forte Biosciences, Inc. and its subsidiaries (www.fortebiorx.com) (“Forte”, “we”, “our”) is a biopharmaceutical company that is advancing…View ↗
Loading...
